Interactions between corticotropin releasing factor signaling and prophylactic antibiotics on measures of intestinal function in weaned and transported pigs.

Article

作者: McConn, Betty R ; Radcliffe, John S ; Richert, Brian T ; Lay, Donald C ; Behan, Dominic P ; Rivier, Jean E ; Kpodo, Kouassi R ; Johnson, Jay S

The study objective was to evaluate the interaction between corticotrophin releasing factor (CRF) receptor signaling and prophylactic antibiotic administration on intestinal physiology in newly weaned and transported pigs. Pigs (n = 56; 5.70 ± 1.05 kg) were weaned (20.49 ± 0.64 d), a blood sample was taken, and then pigs were given an intraperitoneal injection of saline (SAL; n = 28 pigs) or a CRF receptor antagonist (CRFA; n = 28 pigs; 30 μg/kg body weight; Astressin B), and then were transported in a livestock trailer for 12 h and 49 min. A second and third intraperitoneal injection was given at 4 h 42 min and 11 h 36 min into the transport process, respectively. Following transport, 4 SAL and 4 CRFA pigs were blood sampled and euthanized. The remaining 48 pigs were individually housed and given dietary antibiotics [AB; n = 12 SAL and 12 CRFA pigs; chlortetracycline (441 ppm) + tiamulin (38.6 ppm)] or no dietary antibiotics (NAB; n = 12 SAL and 12 CRFA pigs) for 14 d post-transport. Blood was collected at 12 h and on d 3, 7, and 14, and then pigs were euthanized on d 7 (n = 24) and d 14 (n = 24) post-weaning and transport. Circulating cortisol was reduced (p = 0.05) in CRFA pigs when compared to SAL pigs post-weaning and transport. On d 7, jejunal villus height and crypt depth was greater overall (p < 0.05) in AB-fed pigs versus NAB-fed pigs. On d 14, ileal crypt depth was reduced (p = 0.02) in CRFA pigs when compared to SAL pigs. Jejunal CRF mRNA abundance tended to be reduced (p = 0.09) on d 7 in CRFA pigs versus SAL pigs. On d 14, jejunal tumor necrosis factor-alpha was reduced (p = 0.01) in AB-fed pigs versus NAB-fed pigs. On d 7, change in glucose short-circuit current tended to be increased (p = 0.07) in CRFA pigs fed the AB diet when compared to CRFA pigs fed the NAB diet. In conclusion, CRFA pigs and pigs fed AB had some similar biological intestinal function measures post-weaning and transport.

2020-11-30·Journal of Animal Science

154 Evaluating the effects of prophylactic antibiotics on intestinal health in pigs given a corticotropin-releasing factor antagonist during weaning and transport

作者: McConn, Betty R ; Behan, Dominic P ; Lay, Donald C ; Richert, Brian T ; Johnson, Jay S ; Rivier, Jean E ; Radcliffe, John S

AbstractProphylactic antibiotics improve intestinal health in pigs; however, it is unknown whether their efficacy interacts with a pig’s stress response following weaning and transport. The study objective was to determine whether a corticotropin-releasing factor (CRF) antagonist would impact the efficacy of prophylactic antibiotics on improving intestinal health in transported weaned pigs. Mixed-sex pigs (n = 56; 5.70 ± 1.05 kg BW) were weaned (20.49 ± 0.64 d), a blood sample was taken, pigs were given an i.p. injection of saline (SAL) or a CRF antagonist (CRFA; 30 µg/kg BW; Astressin B), and then were transported for 12 h. Pigs were given a second and third i.p. injection at 6 and 12 h of transport, respectively. Following transport, 4 SAL and 4 CRFA pigs were blood sampled and euthanized. The remaining 48 pigs were individually housed and assigned to an antibiotic [A; chlortetracycline (441 ppm) + tiamulin (38.6 ppm)] or no antibiotic (NA) diet treatment balanced by injection treatment (n = 12 pigs/treatment combination). Blood was collected at 12 h and on d 3, 7, and 14 and pigs were euthanized on d 7 (n = 24) and d 14 (n = 24) post-weaning and transport. Plasma adrenocorticotropic hormone was reduced overall (P = 0.05; 9.1%) in CRFA versus SAL pigs. On d 7, jejunal villus height was greater (P = 0.04; 33%) in A versus NA pigs. Jejunal zonula occludens-1 (58.8%) and ileal claudin-1 (100.5%) mRNA abundance tended to be increased (P = 0.09) in CRFA+NA versus SAL+NA pigs on d 7. On d 14, jejunal tumor necrosis factor-alpha mRNA abundance was reduced (P = 0.02; 29.9%) in A versus NA pigs and jejunal glucagon-like peptide-2 mRNA abundance was increased (P = 0.03) in CRFA+NA versus SAL+NA (48.4%) and SAL+A versus SAL+NA (55.8%) pigs. No intestinal health parameter differences were detected (P > 0.05) between CRFA+NA and SAL+A pigs. In conclusion, CRFA and A impacted weaned pig intestinal health measures at similar levels.

项与 Sentia Medical Sciences, Inc. 相关的新闻（医药）

2024-04-17

·GlobeNewswire-Health Care

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

April 16, 2024 -- Sentia Medical Sciences Inc. today announced that they have further extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicines with the potential to treat a variety of hypothalamic-pituitary-adrenal (HPA) axis modulated diseases. Under the terms of the research collaboration extension, Sentia and Neurocrine will continue to work together to discover novel peptide antagonists targeting CRF and advance them to development candidate stage, after which Neurocrine would be solely responsible for all further development, manufacturing, regulatory and commercial activities. As part of the collaboration, Sentia will continue to receive committed research funding from Neurocrine to support discovery efforts. Sentia is eligible to receive milestone and royalty payments based on products developed from this collaboration. “We are delighted to further extend this important collaboration focused on the discovery and development of novel peptide therapeutics to address HPA-driven diseases and other potential indications with disrupted CRF physiology” said Dominic P. Behan, Ph.D., D.Sc., Chief Executive Officer of Sentia Medical Sciences. Sentia Medical Sciences Inc. is a privately held company with a vision to be a world leader in the development of novel peptide therapeutics to manage and cure stress-related diseases (www.sentiamedical.com). The content above comes from the network. if any infringement, please contact us to modify.

多肽偶联药物引进/卖出

2023-02-14

·BioSpace

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

SAN DIEGO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicines with the potential to treat a variety of hypothalamic-pituitary-adrenal (HPA) axis modulated diseases. Under the terms of the research collaboration extension, Sentia and Neurocrine will continue to work together to discover novel peptide antagonists targeting CRF and advance them to development candidate stage, after which Neurocrine would be solely responsible for all further development, manufacturing, regulatory and commercial activities. As part of the collaboration, Sentia will continue to receive committed research funding from Neurocrine to support discovery efforts. Sentia is eligible to receive milestone and royalty payments based on products developed from this collaboration. “We are delighted to extend this important collaboration focused on the discovery and development of novel peptide therapeutics to address HPA-driven diseases,” said Dominic P. Behan, Ph.D., D.Sc., Chief Executive Officer of Sentia Medical Sciences. About Sentia Medical Sciences Sentia Medical Sciences Inc. is a privately held company with a vision to be a world leader in the development of novel peptide therapeutics to manage and cure stress-related diseases ( ). Contact: Sentia Medical Sciences Inc. info@sentiamedical.com

多肽偶联药物引进/卖出

100 项与 Sentia Medical Sciences, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Sentia Medical Sciences, Inc. 相关的转化医学

登录后查看更多信息